International Clinical Trial: Value of combined GP?a/CYP2C19 polymorphisms for AIS short-term prognosis and recurrence

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131744) titled 'Value of combined GP?a/CYP2C19 polymorphisms for AIS short-term prognosis and recurrence' on Sept. 6.

Study Type: Observational study

Study Design: Case-Control study

Primary Sponsor: Ningbo Medical Centre Lihuili Hospital

Condition: acute ischemic stroke

Intervention: First-episode stroke group:N/A

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-05-01

Target Sample Size: First-episode stroke group:500;Recurrent stroke group:250;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=304625

Published by HT Digital Content Se...